Patients who cannot give valid written informed consent, Patients with a previous history of more than one SARS-CoV-2 infection Patients with nasosinusal diseases such as chronic rhinosinusitis or nasal masses, History of previous traumatic brain injury with olfactory sequelae, History of olfaction disorder prior to SARS CoV-2 infection, Patients with any diagnosed neurological disease known to affect olfactory function, Patients unable to read Portuguese, Patients who are already using an oral glucocorticoid, Patients who have already started some form of therapy for the olfactory disorder caused by COVID-19, Known hypersensitivity to any item used in any of the proposed olfactory training,

Patients who cannot give valid written informed consent, Patients with a previous history of more than one SARS-CoV-2 infection Patients with nasosinusal diseases such as chronic rhinosinusitis or nasal masses, History of previous traumatic brain injury with olfactory sequelae, History of olfaction disorder prior to SARS CoV-2 infection, Patients with any diagnosed neurological disease known to affect olfactory function, Patients unable to read Portuguese, Patients who are already using an oral glucocorticoid, Patients who have already started some form of therapy for the olfactory disorder caused by COVID-19, Known hypersensitivity to any item used in any of the proposed olfactory training,